The Altos Therapeutics /Takeda D2/D3 receptor antagonist, TAK-906 , is a peripherally-restricted, non-BBB penetrant molecule, targeting the stomach and vomiting center in the area postrema to treat gastroparesis. Gastroparesis is a chronic condition characterized by delayed gastric emptying, resulting in nausea, vomiting, pain, and anorexia [...]
< 1 minute read
Dec. 16, 2021
TAK-906: A Peripherally-Restricted, Non-BBB Penetrant D2/D3 Receptor Antagonist
TAK-906
peripherally-restricted D2/D3 antagonist oral agent for gastroparesis in Ph. II up to 100 mg PO BID JPET, Clinical Pharmacology Altos Therapeutics / Takeda, Cambridge
Reviewer: